EX-10.17 15 d568134dex1017.htm EX-10.17 Confidential Treatment Requested Evelo Biosciences, Inc. EXCLUSIVITY AND COMMITMENT AGREEMENTExclusivity and Commitment Agreement • May 5th, 2020 • England
This Exclusivity and Commitment Agreement (the “Agreement”) is entered into as of February 15, 2018 (the “Effective Date”), by and between Biose Industrie, a French corporation with offices at Rue des Freres Lumieres 15130 Arpajon sur Cere France registered under number B 529 243 271 (“Biose” or “Company”) and Evelo Biosciences, Inc., a Delaware company with a principal place of business at 620 Memorial Drive, Cambridge, Massachusetts 02139 USA (“Evelo”). Evelo and Biose are each individually a “Party” and collectively referred as “Parties”.
AMENDMENT NO. 1 TO EXCLUSIVITY AND COMMITMENT AGREEMENTExclusivity and Commitment Agreement • November 5th, 2019 • Evelo Biosciences, Inc. • Pharmaceutical preparations
This Amendment No. 1 to an Exclusivity and Commitment Agreement is entered into as of August 1, 2019 by and between Biose Industrie, a French corporation with offices at rue des Freres Lumieres 15130, Arpajon sur Cere, France (registration number B529 243 271) ("Biose") and Evelo Biosciences, Inc. a Delaware corporation with a principal place of business at 620 Memorial Drive, Cambridge, Massachusetts 02139, USA ("Evelo"). Evelo and Biose are each individually a "Party" and collectively referred to as the "Parties".
